Lungpacer Medical

What Lungpacer Medical does

Lungpacer Medical is a privately held medical device company founded in 2009 as a Simon Fraser University spinout, headquartered in Vancouver, Canada with U.S. operations based in Exton, Pennsylvania. The company develops temporary transvenous diaphragm neurostimulation (TTDN) systems that stimulate the phrenic nerves via a catheter-based approach to activate and strengthen the diaphragm in mechanically ventilated adult patients, addressing diaphragm atrophy (which can reach 50% within one day of mechanical ventilation) and weaning failure. Its flagship product, the AeroPace System, received FDA Premarket Approval in December 2024 and is indicated to improve weaning success in patients aged 18+ on mechanical ventilation for 96+ hours who have failed to wean; the system consists of an airway pressure sensor, a touchscreen neurostimulation console, and a temporary transvenous catheter with 30 specialized electrodes in two arrays delivering two sets of 60 stimulations daily. A next-generation AeroNova system is in Phase 2 (STARI) feasibility trials and a SupAira application targets organ donor lung management, both backed by BARDA funding and the DONATE study respectively.

The company sells the AeroPace System directly to U.S. hospitals through a field sales organization that includes clinical specialists and reimbursement support staff, with CMS NTAP approval (effective October 1, 2025) enabling up to $23,650.90 in additional Medicare reimbursement per case under the new ICD-10-PCS code X2H13XB. Its go-to-market is enterprise field sales targeted at ICU and critical care departments at major U.S. medical centers, complemented by clinical conference presentations (AJRCCM publication, ATS, THT, Critical Care Reviews Meeting, American Transplant Congress) and earned media including a Wall Street Journal profile. Revenue is generated primarily from hardware sales (neurostimulation console plus single-patient-use catheter) with bundled clinical training and reimbursement support services. The company is led by CEO Doug Evans and a management team with track records of medtech exits at Kensey Nash, Intact Vascular, Ventec Life Systems, and Ceribell, and has raised approximately $150M+ across disclosed funding rounds since inception.

Name

Lungpacer Medical

Legal name

Lungpacer Medical Inc.

Website

https://lungpacer.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Lungpacer Medical is a Vancouver-based medical device company that develops FDA-approved temporary transvenous diaphragm neurostimulation systems (AeroPace) to help mechanically ventilated adults wean from ventilation by activating and strengthening the diaphragm, selling directly to U.S. hospital ICUs.

Ownership category

akta.pro rank

Product category

Respiratory / Critical Care Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts) (HLAHADAJ)

akta.pro secondary industries

Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home) (HLAHAGAC), Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management (HLAKANAM)

Keywords

• Diaphragm neurostimulation devices
• Ventilator weaning systems
• Respiratory medical devices
• Critical care neurostimulation
• Mechanical ventilation therapy

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

1. AeroPace Neurostimulation System (Hardware + Procedure): Revenue is generated from the sale of the AeroPace Neurostimulation System hardware (neurostimulation console and temporary transvenous catheter) to hospitals for use in ICU settings. The system is a single-patient-use device. Hospitals receive CMS NTAP reimbursement of up to $23,650.90 per eligible case under Medicare, and Lungpacer captures revenue from hospital procurement of the system and consumables.
2. Professional Services and Clinical Support: Lungpacer provides clinical training, reimbursement support, and field clinical specialist services to hospitals adopting the AeroPace system, supporting successful implementation and utilization.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels8 records

Core offering

Lungpacer Medical develops and sells the AeroPace Neurostimulation System, an FDA-approved temporary transvenous diaphragm neurostimulation (TTDN) device that stimulates the phrenic nerves via a catheter-based approach to activate and strengthen the diaphragm in adult patients on prolonged mechanical ventilation (≥96 hours) who have failed to wean. The system comprises three components (airway pressure sensor, touchscreen neurostimulation console, and temporary transvenous catheter with 30 electrodes) that integrate into existing ICU workflows without surgical implantation. The company is also developing next-generation AeroNova and SupAira systems extending the platform to earlier-stage ventilation and organ donor management.

Product overview

Lungpacer Medical offers a portfolio of neurostimulation-based medical devices designed to address diaphragm dysfunction in critically ill patients. The flagship product is the FDA-approved AeroPace System, a temporary transvenous diaphragm neurostimulation device that helps mechanically ventilated patients wean from ventilation by stimulating the phrenic nerves to strengthen the diaphragm. The portfolio includes the investigational AeroNova System for continual diaphragm neurostimulation during mechanical ventilation, and the SupAira System application for organ donor management. The AeroPace System integrates three components (airway pressure sensor, neurostimulation console, and temporary transvenous catheter) that work with standard ventilators in ICU workflows.

Differentiator

Problem solved

Functional benefit

Brands

• AeroPace System: FDA-approved temporary transvenous diaphragm neurostimulation system for mechanically ventilated patients to improve weaning success
• AeroNova System
• SupAira System

Products and services

• AeroPace Neurostimulation System FDA-approved temporary transvenous diaphragm neurostimulation (TTDN) system that stimulates the phrenic nerves via a catheter-based approach to activate and strengthen the diaphragm in adult patients on mechanical ventilation for ≥96 hours who have failed to wean. Comprises an airway pressure sensor, touchscreen neurostimulation console, and temporary transvenous catheter with 30 specialized electrodes in two arrays. Indicated for hospital ICU use.
• AeroNova System Investigational next-generation continual diaphragm neurostimulation system designed to deliver therapy in conjunction with mechanical ventilation at reduced positive pressures, intended to mitigate multi-organ ventilator-induced injury (diaphragm, cardiac, and brain) from the earliest stages of mechanical ventilation. Currently in Phase 2 STARI clinical trial.
• SupAira System Application of Lungpacer's transvenous neurostimulation technology for respiratory management of brain-dead organ donors, using temporary transvenous phrenic nerve stimulation to activate the diaphragm during donor management in order to improve oxygenation, reduce atelectasis, and increase transplantable lung yield.

Quantifiable outcome

• 43% faster weaning from mechanical ventilation over 30 days
• +8 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Mid-America TransplantcoreStrategic or Co-development Partner · 23 June 2026Mid-America Transplant in St. Louis, MO served as the research partner for the DONATE clinical study evaluating SupAira diaphragm neurostimulation in 50 brain-dead organ donors. Gary F. Marklin, MD, Chief Medical and Research Officer at Mid-America Transplant, presented the DONATE findings at the American Transplant Congress 2026. The study demonstrated that diaphragm neurostimulation significantly increased donor lungs meeting transplant criteria compared to matched contemporary controls.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• TransMedics: TransMedics is a leader in organ transplant logistics and ex-vivo organ perfusion. While its technology differs from Lungpacer's SupAira diaphragm neurostimulation, both companies target the lung transplant ecosystem — TransMedics via organ preservation, Lungpacer via improving donor lung utilization through neurostimulation.
• Inspire Medical Systems: Inspire Medical Systems commercializes an implantable neurostimulation device for obstructive sleep apnea. While it targets a different patient population (sleep apnea vs. ICU weaning), it is a relevant comparable as a neurostimulation-based medical device company that built a successful commercial franchise around pharyngeal nerve stimulation.

Direct peers

• Synapse Biomedical: Synapse Biomedical manufactures the NeuRx Diaphragm Pacing System (DPS), a phrenic nerve stimulation device for diaphragm conditioning. While NeuRx requires surgical laparoscopic implantation versus Lungpacer's transvenous approach, it is the most direct competing technology for diaphragm neurostimulation in ventilated patients.
• Avery Biomedical Devices: Avery Biomedical Devices produces implantable diaphragm pacemakers (Mark IV Breathing Pacemaker) that stimulate the phrenic nerve, primarily for spinal cord injury and central sleep apnea patients. It competes in the broader diaphragm neurostimulation category though its surgical implant approach differs from Lungpacer's catheter-based temporary system.

Broad incumbents

• Medtronic: Medtronic has historically been a leading player in diaphragm pacing through its acquisition of Synapse Biomedical-related IP and has a broad respiratory and ICU portfolio. As a major medtech incumbent with deep hospital relationships, it represents both a potential competitor and a strategic acquirer for the diaphragm neurostimulation category.
• Getinge: Getinge is a global leader in ICU ventilation with products like the Servo-i and Servo-u ventilator platforms used in critical care. As a dominant ventilator supplier, Getinge is a natural channel partner or potential competitor in advanced respiratory care adjuncts targeting mechanically ventilated patients.
• Dräger: Dräger is a major manufacturer of ICU ventilators (Evita, Oxylog, Babylog families) and acute care equipment. Its installed base in critical care units globally makes it a relevant incumbent that could expand into diaphragm neurostimulation adjuncts or partner with Lungpacer for ventilator-integrated solutions.
• Hamilton Medical: Hamilton Medical manufactures intelligent ICU ventilators (HAMILTON-C1, G5, C6) with a global footprint in critical care. Its installed base and ICU integration expertise position it as an incumbent comparable to Lungpacer's customer-facing environment, though it does not currently offer a diaphragm neurostimulation product.
• Vyaire Medical: Vyaire Medical is a respiratory care company offering ventilators (Bellavista, Avea) and respiratory diagnostics. Its focus on the ICU ventilation market and broad product portfolio make it a relevant comparable for companies selling into critical care departments.
• Philips Respironics: Philips, through its Respironics franchise, has been a leading player in respiratory care including non-invasive ventilation and hospital ventilation. Its scale and hospital relationships make it a meaningful comparable in the broader ICU respiratory care market, even though it does not currently offer diaphragm neurostimulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/lungpacer
• YouTubeyoutube.com/channel/UC1KpsISfhJGAc02M1YB29PA
• LinkedInlinkedin.com/company/lungpacer-medical-inc.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lungpacer Medical